Skip to main content
. 2021 May 14;7(5):383. doi: 10.3390/jof7050383

Table 2.

In vitro susceptibility of Candida spp. isolates to Ruta graveolens essential oil and antifungal drugs.

Strains Ruta graveolens (REO) (µg/mL) MFC Amphotericin B (µg/mL) MFC Fluconazole (µg/mL) MFC Voriconazole (µg/mL) MFC
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
C. albicans ORL02 8.2 ± 0.5 12.3 ± 0.5 0.5 ± 0.25 0.5 ± 0.25 0.5 ± 0.25 1 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. albicans ORL03 8.2 ± 0.5 8.2 ± 0.5 1 ± 0.5 0.5 ± 0.25 0.5 ± 0.25 1 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. albicans ORL05 8.2 ± 0.5 12.3 ± 0.5 0.5 ± 0.25 1 ± 0.5 0.5 ± 0.25 1 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. albicans ORL07 8.2 ± 0.5 16.4 ± 0.5 1 ± 0.5 1.5 ± 0.5 0.5 ± 0.25 1 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. albicans ORL08 8.2 ± 0.5 8.2 ± 0.5 0.5 ± 0.25 0.5 ± 0.25 1 ± 0.5 1.5 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. albicans ORL09 8.2 ± 0.5 8.2 ± 0.5 0.5 ± 0.25 0.5 ± 0.25 1 ± 0.5 1.5 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. glabrata ORL02 131 ± 1 131 ± 1 2 ± 0.5 1 ± 0.5 128 ± 2 128 ± 2 2 ± 0.5 4 ± 0.5
C. glabrata ORL11 131 ± 1 131 ± 1 2 ± 0.5 1 ± 0.5 128 ± 2 256 ± 2 2 ± 0.5 4 ± 0.5
C. glabrata ORL15 66 ± 1 131 ± 1 1 ± 0.5 1 ± 0.5 128 ± 2 128 ± 2 1 ± 0.5 2 ± 0.5
C. glabrata ORL20 131 ± 1 131 ± 1 2 ± 0.5 1 ± 0.5 128 ± 2 256 ± 2 2 ± 0.5 4 ± 0.5
C. glabrata ORL22 131 ± 1 131 ± 1 1 ± 0.5 1 ± 0.5 128 ± 2 256 ± 2 1 ± 0.5 4 ± 0.5
C. glabrata ORL13 131 ± 1 131 ± 1 2 ± 0.5 1 ± 0.5 128 ± 2 256 ± 2 2 ± 0.5 4 ± 0.5
C. tropicalis ORL18 4.1 ± 0.25 8.2 ± 0.5 0.5 ± 0.25 1 ± 0.5 1 ± 0.5 2 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. tropicalis ORL19 66 ± 0.5 8.2 ± 0.5 1 ± 0.5 1 ± 0.5 1 ± 0.5 2 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. tropicalis ORL20 4.1 ± 0.25 8.2 ± 0.5 0.5 ± 0.25 1 ± 0.5 1 ± 0.5 2 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. tropicalis ORL21 4.1 ± 0.25 8.2 ± 0.5 1 ± 0.5 1 ± 0.5 1 ± 0.5 2 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. tropicalis ORL22 4.1 ± 0.25 8.2 ± 0.5 0.5 ± 0.25 1 ± 0.5 1 ± 0.5 2 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. tropicalis ORL23 4.1 ± 0.25 8.2 ± 0.5 0.5 ± 0.25 1 ± 0.5 2 ± 0.5 2 ± 0.5 0.03 ± 0.005 0.03 ± 0.005
C. parapsilosis ORL25 16.4 ± 0.5 20.5 ± 0.5 0.5 ± 0.25 1 ± 0.5 2 ± 0.5 4 ± 0.5 0.125 ± 0.05 0.250 ± 0.05
C. parapsilosis ORL25 16.4 ± 0.5 16.4 ± 0.5 1 ± 0.5 1 ± 0.5 2 ± 0.5 4 ± 0.5 0.125 ± 0.05 0.250 ± 0.05
C. parapsilosis ORL27 16.4 ± 0.5 20.5 ± 0.5 0.5 ± 0.25 1 ± 0.5 2 ± 0.5 4 ± 0.5 0.125 ± 0.05 0.250 ± 0.05
C. parapsilosis ORL28 16.4 ± 0.5 16.4 ± 0.5 0.5 ± 0.25 1 ± 0.5 2 ± 0.5 4 ± 0.5 0.125 ± 0.05 0.250 ± 0.05
C. parapsilosis ORL29 16.4 ± 0.5 16.4 ± 0.5 0.5 ± 0.25 1 ± 0.5 2 ± 0.5 4 ± 0.5 0.125 ± 0.05 0.250 ± 0.05
C. parapsilosis ORL30 16.4 ± 0.5 20.5 ± 0.5 0.5 ± 0.25 1 ± 0.5 2 ± 0.5 4 ± 0.5 0.125 ± 0.05 0.250 ± 0.05